NCT02837042 2022-06-21
Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma
University of Alabama at Birmingham
Phase 2 Terminated
Clinical Trials
8 trialsNCT03937791 2021-04-13
Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01111058 2020-04-07
Everolimus Versus Placebo in Head and Neck Cancer
University of Chicago
Phase 2 Terminated
NCT01581970 2019-09-11
Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT00661427 2018-01-11
Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00591149 2017-06-14
Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer
University of Kansas Medical Center
Phase 2 Terminated
NCT00485485 2012-08-07
Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00229723 2009-08-04
IRESSAâ„¢ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma
AstraZeneca
Phase 2 Completed